普洛藥業(000739.SZ):目前正在籌建PROTAC/ADC/多肽等平台
格隆匯3月13日丨普洛藥業(000739.SZ)於2023年3月9日19:00-20:00舉行投資者電話交流會並表示,公司2022年的研發投入5.33億元,同比增長19.43%,佔營業收入的5.05%。研發人員1026人,其中博士46人,碩士220人。三大工程技術平台包括流體化學技術平台、晶體和粉體技術平台、合成生物學及酶催化技術平台開始正常運行,兩大支持平台包括安全實驗和分析測試中心運作良好,對公司各項業務起到較好的支持作用。目前公司也正在籌建PROTAC/ADC/多肽等平台。
2022年公司資本開支超過12億元,2021年約11億。產能建設上已有兩條API生產線投入使用,另有兩條線也在調試中。CDMO一條線投入使用,橫店第二條柔性生產線、研發大樓和高活生產線已建成,在調試中。製劑的一條國際化生產線擴產完成投入使用,一條注射劑生產線已完成,預計能夠在2023年一季度投入使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.